Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valter Torri

Showing results (11-20 of 228) with videos related to

Pageof 23
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2020
To Continue or Not to Continue? That Is the QuestionMarina Chiara Garassino, Benjamin Besse, Valter Torri
Epidemiologia E Psichiatria Sociale|March 22, 2003
[Explanatory model of the cost variability of treating patients: methodology and results]Alessandra Di Maio, Antonio Lora, Valter Torri
The Lancet. Oncology|June 9, 2015
EGFR mutations and EGFR tyrosine kinase inhibitorsValter Torri, Massimo Broggini, Marina Chiara Garassino
Lancet (London, England)|September 20, 2011
Antibiotics versus surgery for appendicitisRita Banzi, Valter Torri, Vittorio Bertele', et al.
Lancet (London, England)|January 13, 2009
Exenatide for type 2 diabetesSilvio Garattini, Vittorio Bertele', Irene Floriani, et al.
Lancet (London, England)|May 20, 2023
DESTINY-Breast03 trial: some questions remainSerena Di Cosimo, Giovanni Apolone, Vera Cappelletti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Effectiveness of adjuvant fluorouracil in elderly colon cancer patients: the internal and external validity of nonrandomized research designGiovanni Apolone, Silvio Cavuto, Valter Torri, et al.
Cancer Research|October 17, 2018
Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition ActivityMarina Chiara Garassino, Valter Torri, Mario Paolo Colombo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 7, 2024
Commentary on "Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC"Robert B Cameron, Jacobi B Hines, Valter Torri, et al.
Cancer Treatment Reviews|October 12, 2013
The impact of personalized medicine on survival: comparisons of results in metastatic breast, colorectal and non-small-cell lung cancersAntonio Rossi, Valter Torri, Marina Chiara Garassino, et al.
Pageof 23

Showing results (11-20 of 228) with videos related to

Sort By:
Pageof 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2020
To Continue or Not to Continue? That Is the QuestionMarina Chiara Garassino, Benjamin Besse, Valter Torri
Epidemiologia E Psichiatria Sociale|March 22, 2003
[Explanatory model of the cost variability of treating patients: methodology and results]Alessandra Di Maio, Antonio Lora, Valter Torri
The Lancet. Oncology|June 9, 2015
EGFR mutations and EGFR tyrosine kinase inhibitorsValter Torri, Massimo Broggini, Marina Chiara Garassino
Lancet (London, England)|September 20, 2011
Antibiotics versus surgery for appendicitisRita Banzi, Valter Torri, Vittorio Bertele', et al.
Lancet (London, England)|January 13, 2009
Exenatide for type 2 diabetesSilvio Garattini, Vittorio Bertele', Irene Floriani, et al.
Lancet (London, England)|May 20, 2023
DESTINY-Breast03 trial: some questions remainSerena Di Cosimo, Giovanni Apolone, Vera Cappelletti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Effectiveness of adjuvant fluorouracil in elderly colon cancer patients: the internal and external validity of nonrandomized research designGiovanni Apolone, Silvio Cavuto, Valter Torri, et al.
Cancer Research|October 17, 2018
Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition ActivityMarina Chiara Garassino, Valter Torri, Mario Paolo Colombo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 7, 2024
Commentary on "Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC"Robert B Cameron, Jacobi B Hines, Valter Torri, et al.
Cancer Treatment Reviews|October 12, 2013
The impact of personalized medicine on survival: comparisons of results in metastatic breast, colorectal and non-small-cell lung cancersAntonio Rossi, Valter Torri, Marina Chiara Garassino, et al.
Pageof 23